Trial Profile

A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pemigatinib (Primary)
Indications Colorectal cancer
Focus Therapeutic Use

Most Recent Events

21 Jan 2023 Primary endpoint has not been met. (Overall response rate (ORR)) , according to Results presented at the 2023 Gastrointestinal Cancers Symposium
21 Jan 2023 Status changed to discontinued , according to presented at the 2023 Gastrointestinal Cancers Symposium
21 Jan 2023 Results (n=14) reporting safety and efficacy data in patients who were enrolled in the first stage of the study presented at the 2023 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com